Case Overview

The Parties

The Patents at Issue

This landmark case involved thirteen U.S. patents covering the MYCAPSSA (octreotide) delayed-release capsule technology. This layered portfolio — spanning application dates from 2011 to 2022 — reflects a classic “patent thicket” strategy designed to extend market exclusivity well beyond any single patent’s expiration. All patents are registered with the U.S. Patent and Trademark Office (USPTO).

• • US8,329,198, US8,535,695 — foundational octreotide formulation patents
• • US9,265,812, US9,566,246 — delivery mechanism and formulation refinements
• • US10,238,709, US10,695,397 — extended therapeutic use claims
• • US11,052,126, US11,141,457, US11,338,011 — manufacturing and dosage form innovations
• • US11,510,963, US11,857,595, US11,890,316, US11,969,471 — continuation patents extending coverage through recent prosecution

The Verdict & Legal Analysis

Outcome

On July 24, 2024, the court entered a Consent Judgment and Permanent Injunction — the functional equivalent of a plaintiff’s victory achieved through negotiated resolution. All claims and counterclaims were dismissed with prejudice, with no award of costs or attorney fees to either party.

Key injunctive relief provisions include Teva being permanently enjoined from making, using, selling, offering for sale, importing, or distributing its ANDA product in the United States until expiration of all 13 patents-in-suit. No monetary damages were disclosed, consistent with consent judgments in Hatch-Waxman litigation where no commercial sales occurred.

Verdict Cause Analysis

This was a straightforward infringement action under the Hatch-Waxman Act (21 U.S.C. § 355(j)). By filing a Paragraph IV certification against Chiesi’s listed patents, Teva triggered the statutory infringement presumption, placing itself in the position of defending validity and non-infringement across all 13 asserted patents simultaneously.

The consent judgment’s breadth — covering all 13 patents without carving out any as invalid or not infringed — suggests Teva did not identify a viable invalidity or non-infringement position strong enough to justify full litigation costs. The retention of Paragraph IV certification rights under the consent judgment’s Paragraph 8 is a notable carve-out, preserving Teva’s procedural posture for potential future USPTO challenges (e.g., IPR petitions) without conceding patent validity.

Legal Significance

• • Portfolio depth as litigation deterrent: Thirteen patents covering a single drug product creates an enormous invalidity burden. Successfully challenging even a subset of patents is insufficient when others remain valid and infringed.
• • Paragraph IV certification preservation: Despite the injunction, Teva retained the right to maintain its Paragraph IV certifications — a standard but strategically important provision allowing future PTAB proceedings without triggering contempt.
• • FDA approval not restricted: The consent judgment explicitly preserves FDA’s authority to approve ANDA No. 217507, meaning Teva’s product could legally receive regulatory approval but remains commercially blocked by the injunction. This distinction matters for future patent expiration planning.
• • No admission of infringement or invalidity: The consent structure avoids creating direct precedent on claim construction or validity, limiting its precedential impact while fully protecting Chiesi’s commercial interests.